Eton Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

false 0001710340 0001710340 2025-06-10 2025-06-10

 

 

 

 

 

 

 

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

The 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Eton Pharmaceuticals, Inc. (the “Company”) was held virtually on June 10, 2025. At the meeting, the Company’s stockholders (1) elected the director nominee Paul V. Maier for a three-year term and (2) ratified the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

 

The results for each of the matters voted upon by the Company’s stockholders at the Annual Meeting were as follows:

 

 

 

Proposal 2: Ratification of the Appointment of Crowe LLP as the Company’s Independent Registered Public Accounting Firm for the year ending December 31, 2025

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.